This content is machine translated Psoriasis treatment with biologics What are the latest trends? Novel oral therapies are currently being researched – promising data from clinical trials is now available. In the field of approved, subcutaneously administered IL-23 and IL-17 antagonists, current real-world data...…
View Post 3 min This content is machine translated Risankizumab as a therapeutic option “Real life” interim balance: PASI 100 – realistic target Risankizumab has been approved in Switzerland since April 2019 for moderate to severe plaque psoriasis after unsuccessful therapy with conventional systemic treatment. The high and long-lasting efficacy with rapid response…
